Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials

Go back to Resources

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

International Multicenter Trial of Islet Transplantation Using the Edmonton Protocol in Patients with Type 1 Diabetes

Go back to Resources

International Multicenter Trial of Islet Transplantation Using the Edmonton Protocol in Patients with Type 1 Diabetes

Authors:

Location:

Go back to Resources

Initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS)

Go back to Resources

Initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS)

Authors:

Location:

Go back to Resources

Initial results of the Protein Kinase C beta Inhibitor Diabetic Macular Edema Study (PKC-DMES)

Go back to Resources

Initial results of the Protein Kinase C beta Inhibitor Diabetic Macular Edema Study (PKC-DMES)

Authors:

Location:

Go back to Resources

Initial results of the Protein Kinase C b Inhibitor Diabetic Retinopathy Study (PKC-DRS)

Go back to Resources

Initial results of the Protein Kinase C b Inhibitor Diabetic Retinopathy Study (PKC-DRS)

Authors:

Location:

Go back to Resources

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration

Go back to Resources

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Horizontal rectus tenotomy in patients with congenital nystagmus (CN): results in ten adults

Go back to Resources

Horizontal rectus tenotomy in patients with congenital nystagmus (CN): results in ten adults

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Results from the Inaugural Year of the Collaborative Islet Transplant Registry (CITR)

Go back to Resources

Results from the Inaugural Year of the Collaborative Islet Transplant Registry (CITR)

Authors:

Location:

Go back to Resources

Results from the 2002-03 Palivizumab Outcomes Registry: focus on congenital airway abnormalities & neuromuscular disease. 2004 Pediatric Academic Societies Meeting

Go back to Resources

Results from the 2002-03 Palivizumab Outcomes Registry: focus on congenital airway abnormalities & neuromuscular disease. 2004 Pediatric Academic Societies Meeting

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Results from the 2002-03 Palivizumab Outcomes Registry: focus on congenital airway abnormalities & neuromuscular disease

Go back to Resources

Results from the 2002-03 Palivizumab Outcomes Registry: focus on congenital airway abnormalities & neuromuscular disease

Authors:

Location:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 138
  • Page 139
  • Page 140
  • Page 141
  • Current page 142
  • Page 143
  • Page 144
  • Page 145
  • Page 146
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions